Related Experiment Video
Updated: Apr 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Daptomycin experience in patients with human immunodeficiency virus and resistant gram-positive infections
Jihad Slim1, Humberto Jimenez2, Darren Culshaw3
1Saint Michael's Medical Center, Infectious Diseases Department Newark, NJ, USA.
Objectives:
This study was conducted to evaluate the clinical experience with daptomycin in the treatment of resistant gram-positive infections (GPIs) in patients with HIV infection.
Methods:
Using a retrospective, multicenter, and observational registry study, investigators assessed outcomes following daptomycin therapy in 78 patients (62 efficacy evaluable) infected with HIV and with resistant GPIs.
Results:
Overall, success rates by infection type were bacteremia 91% (20 of 22), endocarditis 91% (10 of 11), and bone/joint 100% (9 of 9). Success by pathogen was 93% (39 of 42), 93% (14 of 15), and 100% (5 of 5) for methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and methicillin-resistant coagulase-negative staphylococci, respectively. Daptomycin appeared to be well tolerated, with 9% having an adverse event possibly related to daptomycin and 4% discontinuing daptomycin.
Conclusions:
In HIV-infected patients, daptomycin appears to be a useful agent for treating resistant GPIs.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Acute Pyelonephritis II: Diagnostic Studies and Management
Retrovirus Life Cycles
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Estimation of k and VD of Aminoglycosides
Antimicrobial Effectiveness

